Advocacy group pokes holes in Trump's MFN pricing claims
Public Citizen says claims for the drug price savings that are being delivered by Trump's Most Favoured Nation deals with pharma are "a mirage."
Newsletters and Deep Dive digital magazine
Public Citizen says claims for the drug price savings that are being delivered by Trump's Most Favoured Nation deals with pharma are "a mirage."
The complex drug pricing ecosystem means all stakeholders are scrambling to understand how the new regulations and PBMs’ adjustments will impact them.
AstraZeneca's generalised myasthenia gravis (gMG) therapy Klygefa gets CHMP recommendation, alongside several other novel medicines.
Approval may validate the science, but it does not secure commercial success. That outcome is determined by the decisions made before launch.
Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Editor's Picks
Newsletters and Deep Dive
digital magazine